VALN Valuation

Valneva SE

Add to Watchlist

Advanced Chart

8.850

+0.01(0.113%)1D

Overview
Forecast
Valuation
Earnings

VALN Relative Valuation

VALN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VALN is overvalued; if below, it's undervalued.

Historical Valuation

Valneva SE (VALN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.16 is considered Undervalued compared with the five-year average of -227.14. The fair price of Valneva SE (VALN) is between 289.84 to 297.75 according to relative valuation methord. Compared to the current price of 8.77 USD , Valneva SE is Undervalued By 96.97%.

Relative Value

Fair Zone

289.84-297.75

Current Price：8.77

96.97%

Undervalued

-8.57

Trailing

Forward

-19.81

EV/EBITDA

Valneva SE. (VALN) has a current EV/EBITDA of -19.81. The 5-year average EV/EBITDA is -2.01. The thresholds are as follows: Strongly Undervalued below -113.53, Undervalued between -113.53 and -57.77, Fairly Valued between 53.74 and -57.77, Overvalued between 53.74 and 109.50, and Strongly Overvalued above 109.50. The current Forward EV/EBITDA of -19.81 falls within the Historic Trend Line -Fairly Valued range.

-12.19

EV/EBIT

Valneva SE. (VALN) has a current EV/EBIT of -12.19. The 5-year average EV/EBIT is -21.87. The thresholds are as follows: Strongly Undervalued below -127.99, Undervalued between -127.99 and -74.93, Fairly Valued between 31.19 and -74.93, Overvalued between 31.19 and 84.24, and Strongly Overvalued above 84.24. The current Forward EV/EBIT of -12.19 falls within the Historic Trend Line -Fairly Valued range.

3.19

Valneva SE. (VALN) has a current PS of 3.19. The 5-year average PS is 3.89. The thresholds are as follows: Strongly Undervalued below 0.32, Undervalued between 0.32 and 2.11, Fairly Valued between 5.67 and 2.11, Overvalued between 5.67 and 7.46, and Strongly Overvalued above 7.46. The current Forward PS of 3.19 falls within the Historic Trend Line -Fairly Valued range.

-12.60

P/OCF

Valneva SE. (VALN) has a current P/OCF of -12.60. The 5-year average P/OCF is -87.15. The thresholds are as follows: Strongly Undervalued below -1240.03, Undervalued between -1240.03 and -663.59, Fairly Valued between 489.29 and -663.59, Overvalued between 489.29 and 1065.74, and Strongly Overvalued above 1065.74. The current Forward P/OCF of -12.60 falls within the Historic Trend Line -Fairly Valued range.

-10.44

P/FCF

Valneva SE. (VALN) has a current P/FCF of -10.44. The 5-year average P/FCF is -14.33. The thresholds are as follows: Strongly Undervalued below -80.52, Undervalued between -80.52 and -47.42, Fairly Valued between 18.76 and -47.42, Overvalued between 18.76 and 51.85, and Strongly Overvalued above 51.85. The current Forward P/FCF of -10.44 falls within the Historic Trend Line -Fairly Valued range.

Valneva SE (VALN) has a current Price-to-Book (P/B) ratio of 6.75. Compared to its 3-year average P/B ratio of 4.04 , the current P/B ratio is approximately 67.13% higher. Relative to its 5-year average P/B ratio of 6.71, the current P/B ratio is about 0.61% higher. Valneva SE (VALN) has a Forward Free Cash Flow (FCF) yield of approximately -3.73%. Compared to its 3-year average FCF yield of -32.04%, the current FCF yield is approximately -88.35% lower. Relative to its 5-year average FCF yield of -17.58% , the current FCF yield is about -78.77% lower.

6.76

P/B

Median3y

4.04

Median5y

6.71

-3.70

FCF Yield

Median3y

-32.04

Median5y

-17.58

Competitors Valuation Multiple

The average P/S ratio for VALN's competitors is 444.16, providing a benchmark for relative valuation. Valneva SE Corp (VALN) exhibits a P/S ratio of 3.19, which is -99.28% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Sana Biotechnology Inc

Anavex Life Sciences Corp

Loss

822.98M

TSHA.O

Taysha Gene Therapies Inc

132.66

78.60%

796.56M

Performance Decomposition

Market capitalization of VALN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of VALN in the past 1 year is driven by Unknown.